Business
Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in
About this update from Vanda Pharmaceuticals Inc.
[{"type":"text","content":"WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA. \nFor more information on DDW 2019, please refer to https://ddw.org/home.\nAbout Vanda\nVanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com. \nInvestor Contact:Jim KellyExecutive Vice President & Chief Financial OfficerVanda Pharmaceuticals Inc.(202) [email protected]\nMedia Contacts:AJ Jones IIBurson Cohn & Wolfe (BCW)1110 Vermont Avenue, NW, Suite 1200Washington, D.C. [email protected]\nElizabeth Van EveryBurson Cohn & Wolfe (BCW)230 Park Avenue South New York, NY 10003 212-614-3881 [email protected]\n View original content:http://www.prnewswire.com/news-releases/tradipitant-in-the-treatment-of-gastroparesis-vanda-presents-clinical-trial-results-at-ddw-2019-300855295.html\nSOURCE Vanda Pharmaceuticals Inc.\n\n ","length":2810,"tagName":"div"}]